Progestin/Testosterone Transdermal Gel
AssigneesThe Population Council, Inc., The United States of America, as rep'd by the Secy., Dept. of Health and Human Services
InventorsDiana L. Blithe, Ph.d., Min S. Lee, Regine Sitruk-Ware
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.
Claims19
A metered pump canister comprising a transdermal composition for contraceptive treatment of males, wherein the metered pump canister is configured to deliver on actuation a unit dose of the transdermal composition, and the unit dose of the transdermal composition comprises 8 to 8.5 mg of 16-methylene-17α-acetoxy-19-norpregn-4-ene-3, 20-dione and 73.5 to 74.5 mg of testosterone.
A transdermal composition in a unit dose form for contraceptive treatment of males, comprising 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione in an amount of 8 to 8.5 mg, testosterone in an amount of 73.5 to 74.5 mg, and a pharmaceutical acceptable excipient.
Dependencies are inferred from the claim text.